WallStSmart
ITRM

Iterum Therapeutics PLC

NASDAQ: ITRM · HEALTHCARE · BIOTECHNOLOGY

$0.03
+0.00% today

Updated 2026-06-05

Market cap
$3.75M
P/E ratio
P/S ratio
9.62x
EPS (TTM)
$-0.72
Dividend yield
52W range
$0 – $1
Volume
188.4M

Iterum Therapeutics PLC (ITRM) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item201620172018201920202021202220232024
Operating cash flow$-11.30M$-30.60M$-75.89M$-81.92M$-54.53M$-15.84M$-18.47M$-39.33M$-26.77M
Capital expenditures$812000.00$812000.00$90000.00$24000.00$11000.00$61000.00$62000.00$13000.00$2000.00
Depreciation
Stock-based comp$348000.00$392000.00$1.29M$2.17M$2.76M$4.32M$22.11M$784000.00$363000.00
Free cash flow$-12.11M$-31.42M$-75.98M$-81.95M$-54.54M$-15.90M$-18.54M$-39.34M$-26.77M
Investing cash flow
Financing cash flow
Dividends paid
Share repurchases
Debt repayment
Net change in cash$36.29M$-39.76M$9.94M

Frequently asked questions

What is Iterum Therapeutics PLC's revenue?

Iterum Therapeutics PLC's trailing twelve-month revenue is $390000.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How much free cash flow does ITRM generate?

ITRM produced $-26.77M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.